About Novartis institutes for biomedical research (nibr)
Novartis Institutes for BioMedical Research (NIBR) is a global pharmaceutical company that focuses on discovering and developing innovative medicines to improve the lives of patients worldwide. NIBR is a part of Novartis, one of the world's leading pharmaceutical companies with a presence in over 155 countries.
NIBR has been at the forefront of biomedical research for over 20 years, and its mission is to discover new treatments for diseases that have no cure or inadequate treatment options. The company's research efforts are focused on four key therapeutic areas: oncology, neuroscience, immunology, and cardiovascular-metabolic diseases.
One of NIBR's core strengths is its use of powerful new technologies to accelerate drug discovery and development. The company has invested heavily in cutting-edge technologies such as genomics, proteomics, high-throughput screening, and artificial intelligence to identify potential drug targets quickly.
NIBR also collaborates with academic institutions and other industry partners to advance scientific knowledge in various fields. These collaborations help NIBR stay at the forefront of innovation by leveraging expertise from different disciplines.
The company has a strong commitment to patient-centricity and strives to develop medicines that address unmet medical needs. NIBR's researchers work closely with patient advocacy groups to understand patients' needs better and develop therapies that can make a meaningful difference in their lives.
In addition to its focus on drug discovery and development, NIBR also invests in training future scientists through various programs such as internships, fellowships, and postdoctoral positions. These programs provide young scientists with hands-on experience working alongside experienced researchers while contributing towards advancing scientific knowledge.
Overall, Novartis Institutes for BioMedical Research (NIBR) is an innovative pharmaceutical company committed to discovering breakthrough therapies for patients using cutting-edge technologies while collaborating with academic institutions worldwide. Its dedication towards patient-centricity makes it stand out among other pharmaceutical companies globally.